Get startedLog in
    Picture of Alligator Bioscience AB logo

    ATORX — Alligator Bioscience AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Alligator Bioscience: Positive 2nd Interim Efficacy Analysis From Mitazalimab Optimize-1 Phase 2 Study In 1st Line Pancreatic Cancer

    Picture of Alligator Bioscience AB logoAlligator Bioscience AB
    26/06/2023 07:34
    June 26 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * ANNOUNCES POSITIVE SECOND INTERIM EFFICACY ANALYSIS FROM MITAZALIMAB OPTIMIZE-1 PHASE 2
STUDY IN
1ST LINE PANCREATIC CANCER
    * OPTIMIZE-1 REMAINS ON TRACK FOR TOP-LINE READOUT IN EARLY Q1 2024
    * CONTINUED FOLLOW-UP ON FUTILITY ANALYSIS COHORT (23 PATIENTS) SHOWED DEEPENING OF TUMOR
RESPONSES AND AN INCREASE IN OBJECTIVE RESPONSE RATE TO 57% (FROM 52%)

Source text for Eikon:  ID:nMFNbpMMRZ 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Alligator Bioscience AB

    See all news